Minerva Neurosciences, Inc. (NERV) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Minerva Neurosciences, Inc. (NERV) trades at $4.79 with AI Score 22/100 (Grade F). Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. Market cap: $223M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for NERV: NERV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NERV against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NERV: 3/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Minerva Neurosciences, Inc. (NERV) Healthcare & Pipeline Overview
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company specializing in central nervous system (CNS) disorders. Their pipeline features roluperidone for schizophrenia and MIN-301 for Parkinson's disease, positioning them within the competitive biotechnology landscape with a focus on unmet medical needs.
What Is the Investment Thesis for NERV?
Minerva Neurosciences' investment thesis hinges on the successful development and commercialization of roluperidone for schizophrenia and MIN-301 for Parkinson's disease. The company's focus on CNS disorders, an area with significant unmet medical needs, presents a substantial market opportunity. Key value drivers include positive clinical trial results for roluperidone, particularly in addressing negative symptoms of schizophrenia, and advancement of MIN-301 through clinical development. The licensing agreement with Mitsubishi Tanabe Pharma Corporation provides a potential revenue stream and validation of roluperidone's market potential. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $223M and a beta of -0.21, Minerva represents a high-risk, high-reward investment opportunity within the biotechnology sector.
Based on FMP financials and quantitative analysis
NERV Key Highlights
Lead product candidate roluperidone targets the treatment of schizophrenia, addressing a significant unmet need in CNS disorders.
- MIN-301, a soluble recombinant form of the neuregulin-1b1 protein, is being developed for Parkinson's disease and other neurodegenerative disorders.
- Licensing agreement with Mitsubishi Tanabe Pharma Corporation for roluperidone provides potential revenue stream and market access in key regions.
- Market capitalization of $223M reflects the company's early-stage development and associated risks.
- Small team of 8 employees allows for focused execution of clinical programs and strategic initiatives.
Who Are NERV's Competitors?
NERV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NERV's Key Strengths?
Focus on unmet needs in CNS disorders.
- Promising lead product candidate (roluperidone).
- Strategic partnership with Mitsubishi Tanabe Pharma Corporation.
- Experienced management team with expertise in drug development.
What Are NERV's Weaknesses?
Limited financial resources.
- Reliance on a small number of product candidates.
- High risk of clinical trial failures.
- Small number of employees.
What Could Drive NERV Stock Higher?
Clinical trial results for roluperidone in schizophrenia.
- Clinical trial results for MIN-301 in Parkinson's disease.
- Potential regulatory submissions for roluperidone.
- Partnering and licensing opportunities to expand market reach.
What Are the Key Risks for NERV?
Financial-distress signal — its Altman Z-Score of -24.03 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for roluperidone or MIN-301.
- Regulatory delays or rejection of product candidates.
- Competition from established pharmaceutical companies.
- Limited financial resources to support ongoing clinical development.
What Are the Growth Opportunities for NERV?
- Successful clinical development and regulatory approval of roluperidone for schizophrenia represents a significant growth opportunity. The market for schizophrenia treatment is substantial, with a growing need for therapies that address negative symptoms and cognitive impairments. Positive Phase 3 trial results and subsequent FDA approval could drive significant revenue growth for Minerva. The timeline for potential approval is dependent on clinical trial outcomes and regulatory review processes.
- Advancement of MIN-301 through clinical trials for Parkinson's disease and other neurodegenerative disorders presents another growth opportunity. The market for Parkinson's disease treatment is expanding due to the aging population and increasing prevalence of the disease. Successful clinical development of MIN-301 could position Minerva as a key player in the neurodegenerative disease space. The timeline for MIN-301 development depends on clinical trial progress and regulatory milestones.
- Expansion of the licensing agreement with Mitsubishi Tanabe Pharma Corporation to include additional territories or indications could further enhance Minerva's growth prospects. Leveraging strategic partnerships to expand market reach and accelerate commercialization is a key element of Minerva's growth strategy. The potential for expanding the partnership depends on the success of roluperidone in existing markets and the identification of new opportunities.
- Exploration of new product candidates and therapeutic targets within the CNS space represents a long-term growth opportunity for Minerva. Investing in early-stage research and development to identify novel therapies for other neurological disorders could diversify the company's pipeline and reduce reliance on roluperidone and MIN-301. The timeline for new product development is dependent on research progress and funding availability.
- Potential for acquisition or strategic partnership with a larger pharmaceutical company could provide Minerva with access to greater resources and expertise. The biotechnology industry is characterized by frequent mergers and acquisitions, and Minerva's innovative pipeline could make it an attractive target for larger companies seeking to expand their CNS portfolio. The timing of any potential acquisition or partnership is uncertain and depends on market conditions and strategic considerations.
What Threats Does NERV Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expiration and generic competition.
- Changes in healthcare policy and reimbursement.
What Are NERV's Competitive Advantages?
- Proprietary drug candidates targeting specific CNS disorders.
- Licensing agreements with established pharmaceutical companies.
- Expertise in clinical development and regulatory approval of CNS therapeutics.
What Does NERV Do?
Minerva Neurosciences, Inc. was founded in 2007 as Cyrenaic Pharmaceuticals, Inc., later rebranding in 2013 to reflect its evolving focus on neurological disorders. The company is dedicated to the development and commercialization of innovative therapies targeting unmet needs in the treatment of central nervous system (CNS) diseases. Their lead product candidate, roluperidone, is being developed for the treatment of schizophrenia, aiming to address negative symptoms and cognitive impairments associated with the condition. Another key asset in their pipeline is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein, which is under investigation for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva has a licensing agreement with Mitsubishi Tanabe Pharma Corporation for roluperidone, granting them the rights to develop, sell, and import the drug globally, excluding Asia. Headquartered in Waltham, Massachusetts, Minerva operates as a clinical-stage company, advancing its product candidates through rigorous clinical trials to demonstrate safety and efficacy. The company's strategy involves strategic collaborations and licensing agreements to expand its reach and accelerate the development and commercialization of its therapies. With a small team of 8 employees, Minerva focuses on efficient execution of its clinical programs and strategic partnerships.
What Products and Services Does NERV Offer?
- Develop and commercialize product candidates for central nervous system (CNS) diseases.
- Focus on unmet needs in the treatment of schizophrenia and Parkinson's disease.
- Advance roluperidone through clinical trials for the treatment of schizophrenia.
- Develop MIN-301 for the treatment of Parkinson's disease and other neurodegenerative disorders.
- Establish licensing agreements with pharmaceutical companies to expand market reach.
- Conduct research and development to identify new therapeutic targets in the CNS space.
How Does NERV Make Money?
- Develop and out-license novel CNS therapeutics.
- Focus on clinical trials to prove efficacy and safety.
- Partner with larger pharmaceutical companies for commercialization.
What Industry Does NERV Operate In?
Minerva Neurosciences operates within the biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory oversight. The CNS therapeutics market is driven by the increasing prevalence of neurological disorders, such as schizophrenia and Parkinson's disease. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies for CNS disorders. Minerva's focus on specific unmet needs, such as negative symptoms of schizophrenia, differentiates it within the competitive landscape. The biotechnology industry is subject to market trends including precision medicine, gene therapy, and digital health technologies.
Who Are NERV's Key Customers?
- Patients with schizophrenia.
- Patients with Parkinson's disease.
- Pharmaceutical companies seeking to license novel CNS therapeutics.
How Minerva Neurosciences, Inc. Is Valued
Minerva Neurosciences, Inc. carries a market capitalization of $223M, placing it in the micro-cap category. Relative to its peer group, NERV's quantitative score of 22/100 is below the peer average of 74/100.
Company Profile
Minerva Neurosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO Remy Luthringer. NERV has traded publicly since 2014.
Key Financial Metrics
Return on equity for Minerva Neurosciences, Inc. stands at 359.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 17.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -174.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Minerva Neurosciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.03 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Minerva Neurosciences, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 251.0% below estimates on average.
Forward Outlook
Wall Street analysts project Minerva Neurosciences, Inc. revenue of about $19.8M for fiscal 2026, with EPS near $-3.54. The estimate reflects 3 contributing analysts.
NERV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on unmet needs in CNS disorders.
- Promising lead product candidate (roluperidone).
- Strategic partnership with Mitsubishi Tanabe Pharma Corporation.
- Experienced management team with expertise in drug development.
Bear Case
- Limited financial resources.
- Reliance on a small number of product candidates.
- High risk of clinical trial failures.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NERV Latest News
No recent news available for NERV.
NERV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NERV.
Price Targets
Wall Street price target analysis for NERV.
NERV MoonshotScore
What does this score mean?
The MoonshotScore rates NERV 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Remy Luthringer
CEO
Remy Luthringer serves as the CEO of Minerva Neurosciences, bringing extensive experience in the pharmaceutical industry. His background includes leadership roles in various biotechnology and pharmaceutical companies, where he focused on drug development, commercialization, and strategic partnerships. Luthringer's expertise spans across multiple therapeutic areas, with a particular emphasis on central nervous system disorders. He has a proven track record of driving innovation and building successful teams in the biopharmaceutical sector.
Track Record: Under Remy Luthringer's leadership, Minerva Neurosciences has focused on advancing its clinical pipeline, particularly roluperidone for schizophrenia and MIN-301 for Parkinson's disease. Key milestones include securing a licensing agreement with Mitsubishi Tanabe Pharma Corporation for roluperidone and progressing clinical trials for both lead product candidates. Luthringer's strategic decisions have aimed to maximize the value of Minerva's assets and position the company for long-term growth.
What Investors Ask About Minerva Neurosciences, Inc. (NERV) — Healthcare
What does the AI Score mean for NERV?
NERV holds an AI Score of 22/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. Their lead product candidate, roluperidone, targets …
What does Minerva Neurosciences, Inc. do?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Their primary focus is on addressing unmet needs in the treatment of schizophrenia and Parkinson's disease. The company's lead product candidate, roluperidone, is being developed for schizophrenia, targeting negative symptoms and cognitive impairments.
What do analysts say about NERV stock?
Analyst coverage of Minerva Neurosciences (NERV) is limited, reflecting the company's small market capitalization and early-stage development. The consensus view is speculative, contingent on the success of roluperidone's clinical trials and regulatory approval. Key valuation metrics are difficult to assess due to the lack of current revenue and profitability.
What are the main risks for NERV?
Minerva Neurosciences faces several key risks inherent to the biotechnology industry and its specific business model. Clinical trial failures for roluperidone or MIN-301 represent a significant risk, as negative results could halt development and significantly impact the company's value.
What are the key factors to evaluate for NERV?
Minerva Neurosciences, Inc. (NERV) holds an AI score of 22/100 (low). Minerva Neurosciences' investment thesis hinges on the successful development and commercialization of roluperidone for schizophrenia and MIN-301 for Parkinson's disease. Not financial advice.
How frequently does NERV data refresh on this page?
NERV's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NERV's recent stock price performance?
Minerva Neurosciences, Inc. (NERV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on unmet needs in CNS disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NERV overvalued or undervalued right now?
Minerva Neurosciences, Inc. (NERV) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NERV before investing?
Before investing in Minerva Neurosciences, Inc. (NERV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.